MTOR and squamous cell carcinoma: For instance, almost 70% of breast [10] and ovarian cancers [11] carry an alteration of PI3K/AKT; similarly, the aberrant activation of the PI3K/AKT/mTOR pathway has been identified in 90% of lung adenocarcinomas (ADCs) and 40% of squamous cell carcinomas (SCCs) [12], leading to its hyperactivation.